Endocarditis medical therapy: Difference between revisions

Jump to navigation Jump to search
(/* Treatment Based Upon Infectious Agent{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong...)
Line 151: Line 151:
====Nafcillin or Oxacillin + Rifampin + Gentamicin====
====Nafcillin or Oxacillin + Rifampin + Gentamicin====
*Dose: Nafcillin or oxacillin, 12 g I.V. daily in divided doses q. 4 hour for 6–8 weeks plus rifampin, 300 mg p.o., q. 8 hour for 6–8 weeks plus gentamicin (administer during the initial 2 weeks), 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks.
*Dose: Nafcillin or oxacillin, 12 g I.V. daily in divided doses q. 4 hour for 6–8 weeks plus rifampin, 300 mg p.o., q. 8 hour for 6–8 weeks plus gentamicin (administer during the initial 2 weeks), 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks.
{|
|-
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Penicillin-susceptible strain (minimum inhibitory concentration <0.12 >g/mL)}}''
|-
!style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 weeks'''''<BR>''OR''<BR> ▸ '''''[[Ceftriaxone]] 2 g/24 h IV/IM in 1 dose x 6 weeks'''''
|-
|style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''WITH OR WITHOUT''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 1 dose x 2 weeks'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G sodium]] 300 000 U/kg per 24 h IV in 4–6 equally divided doses'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 100
mg/kg IV/IM once daily'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg per
24 h IV/IM, in 1 dose or 3 equally divided doses'''''
|-
!style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | '''''Alternative Regimen'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin|Vancomycin
hydrochloride]] 30 mg/kg per 24 h IV in 2 equally divided doses x 6 weeks'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses'''''


===<u>Staphylococci (Methicillin Resistant) in the Presence of Prosthetic Material</u>===
===<u>Staphylococci (Methicillin Resistant) in the Presence of Prosthetic Material</u>===

Revision as of 18:22, 15 January 2014

Endocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy

Intervention

Case Studies

Case #1

Endocarditis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endocarditis medical therapy

CDC onEndocarditis medical therapy

Endocarditis medical therapy in the news

Blogs on Endocarditis medical therapy

to Hospitals Treating Endocarditis medical therapy

Risk calculators and risk factors for Endocarditis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Ahmed Zaghw, M.D. [3]

Overview

Blood cultures should be drawn prior to instituting antibiotics to identify the etiologic agent and to determine its antimicrobial susceptibility. Older antibiotics such as penicillin G, ampicillin, nafcillin, cefazolin, gentamycin, ceftriaxone, rifampin and vancomycin are the mainstays of therapy.

Timing of Initiation of Antibiotics

Antibiotic therapy for subacute or indolent disease can be delayed until results of blood cultures are known; in fulminant infection or valvular dysfunction requiring urgent surgical intervention, begin empirical antibiotic therapy promptly after blood cultures have been obtained.

Duration of Antibiotic Therapy

The duration for native valve endocarditis is often 4 weeks. For prosthetic valve endocarditis (including the presence of a valve ring), treatment should be continued for 6 to 8 weeks. For each infective agent, the preferred antimicrobial agent, dose, and duration is listed below.

Empirical Antibiotic Therapy

  • Antibiotic therapy for subacute hemodynamically stable disease, and in those who have received antibiotics recently can be delayed waiting the results of blood cultures, as this delay allows an additional blood cultures without the confounding effect of empiric treatment, which is very important in determining the causing pathogens.[1]
  • On the other hand, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.
  • Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.
  • Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.
  • Consultation with an infectious disease specialist for the selection of one of the antibiotic regimens is recommended (see therapy for culture-negative endocarditis). [2]

Treatment Based Upon Infectious Agent[3]

Penicillin-Susceptible Strep Viridans and Other Nonenterococcal Streptococci

Penicillin G

  • If Minimum inhibitory concentration [MIC] <0.2 µg/ml.
  • Dose: 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks.

Penicillin G + Gentamicin

  • Dose: Penicillin G, 12–18 million units I.V. daily in divided doses q. 4 hour for 4 weeks plus gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

Ceftriaxone

  • Dose: 2 g I.V. daily as a single dose for 2 weeks.

Vancomycin

  • Vancomycin can be administered to patients with a history of penicillin hypersensitivity.
  • Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4 weeks.
Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis
Preferred Regimen
penicillin G sodium 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses x 4 weeks
OR
Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 4 weeks
Pediatric dose
penicillin G sodium 200 000 U/kg q24h IV in 4–6 equally divided doses
Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose
Alternative Regimen
Penicillin G sodium 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 weeks
OR
Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 2weeks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose X 2 weeks
Pediatric dose
penicillin G sodium 200 000 U/kg q24h IV in 4–6 equally divided doses
ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose
Alternative Regimen
Vancomycin hydrochloride 15 mg/kg q12h IV x 4 weeks,doses not to exceed 2 g/24 h unless concentrations in serum are inappropriately low
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV in 2–3 equally divided doses

Relatively Penicillin-Resistant Streptococci

Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
Preferred Regimen
Adult:Aqueous crystalline penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks
Pediatrics:Aqueous crystalline penicillin G sodium 300 000 U/24 h IV in 4–6 equally divided doses X 4 Wks
OR
Adult:Ceftriaxone 2 g/24 h IV/IM in 1 dose
Pediatrics:Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
AND
Adult:Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Pediatrics: Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses X 2 Wks
Relatively Penicillin-Resistant Streptococci, MIC > 0.5 µg/ml, consider Enterococcal regimen
Preferred Regimen
Adult:Aqueous crystalline penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks
AND
Adult:Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Unable to tolerate Aqueous crystalline penicillin G sodium or Ceftriaxone
Preferred Regimen
Adult: Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low
Pediatrics: Vancomycin 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks

Enterococci

In general, treatment of enterococcal endocarditis requires combination therapy with two antibiotics:

Penicillin G + Gentamicin

  • Dose is penicillin G, 20–30 million units I.V. daily in divided doses q. 4 hr for 4–6 weeks; gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 4–6 weeks (peak serum concentration should be ~ 3 µg/ml and trough concentrations < 1 µg/ml).

Ampicillin + Gentamicin

  • Dose is ampicillin, 12 g I.V. daily in divided doses q. 4 hour for 4–6 weeks; gentamicin, dose as above.

Vancomycin + Gentamicin

  • This regimen is for patients with history of penicillin hypersensitivity.
  • Dose: Vancomycin, 30 mg/kg I.V. daily in divided doses q. 12 hour for 4–6 weeks; gentamicin, dose as above.

Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material

Nafcillin or Oxacillin + Gentamicin (optional)

  • Dose: Nafcillin or oxacillin, 12 g I.V. daily in divided doses q. 4 hour for 4–6 weeks; gentamicin, 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr for 3–5 days (peak serum concentration should be ~ 3 µg/ml and trough concentrations <1 µg/ml).

Cefazolin + Gentamicin (optional)

  • Alternative regimen for patients with history of penicillin hypersensitivity.
  • Dose: Cefazolin, 12 g I.V. daily in divided doses q. 4 hour for 4–6 weeks; gentamicin, dose as above.

Vancomycin

  • Alternative regimen for patients with history of penicillin hypersensitivity.
  • Dose: 30 mg/kg I.V. daily in divided doses q. 12 hr for 4–6 weeks.

Staphylococci (Methicillin Resistant) in the Absence of Prosthetic Material

Vancomycin

  • Dose: 30 mg/kg I.V. daily in divided doses q. 12 hour for 4–6 weeks.

Staphylococci (Methicillin Susceptible) in the Presence of Prosthetic Material

Nafcillin or Oxacillin + Rifampin + Gentamicin

  • Dose: Nafcillin or oxacillin, 12 g I.V. daily in divided doses q. 4 hour for 6–8 weeks plus rifampin, 300 mg p.o., q. 8 hour for 6–8 weeks plus gentamicin (administer during the initial 2 weeks), 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks.
Penicillin-susceptible strain (minimum inhibitory concentration <0.12 >g/mL)
Preferred Regimen
penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 weeks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 weeks
WITH OR WITHOUT
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 2 weeks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
Ceftriaxone 100

mg/kg IV/IM once daily

Gentamicin 3 mg/kg per

24 h IV/IM, in 1 dose or 3 equally divided doses

Alternative Regimen
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 weeks
Pediatric dose
40 mg/kg per 24 h IV or in 2 or 3 equally divided doses

Staphylococci (Methicillin Resistant) in the Presence of Prosthetic Material

Vancomycin + Rifampin + Gentamicin

  • Dose: Vancomycin, 30 mg/kg I.V. daily in divided doses q. 12 hour for 6–8 weeks plus rifampin, 300 mg p.o., q. 8 hour for 6–8 weeks plus gentamicin (administer during the initial 2 weeks), 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hour for 2 weeks.

HACEK Organisms

HACEK organisms are more indolent and the infection is less complicated.

Ceftriaxone or another Third-Generation Cephalosporin

  • Dose: 2 g I.V. daily as a single dose for 4 weeks.

Ampicillin-Sulbactam

Ciprofloxacin

  • This is listed as an alternative, there is not a lot of data to support its regular use.

Culture Negative Endocarditis

Patients should be divided into 2 groups:

Patients who Received Antibiotic Therapy before the Blood Culture being Drawn
  • Patients with acute clinical presentations with native valve infection: coverage of S. aureus should be followed as detailed in proven staphylococcal disease.
  • Patients with subacute presentation: antibiotic coverage for S. aureus, viridians group streptococci, and enterococci should be considered.
  • Antibiotics for HACEK group of organism also should be considered.
  • Symptomatic patients with prosthetic valve and culture negative infection within 1 year of valve replacement should receive vancomycin to cover the oxacillin-resistant staphylococci.
  • Symptomatic patients with prosthetic valve and culture negative infection within 2 months of valve replacement should also receive cefepime for gram negative bacilli coverage.
  • Symptomatic patients with prosthetic valve more than 1 year, the most likely causing organisms are oxacillin-susceptible staphylococci, viridians group streptococci, and enterococci. Antibiotic coverage for those organisms should be continued for at least 6 weeks.
Patients with Culture-Negative Endocarditis and Suspected Infection with Uncommon Endocarditis Pathogens
  • Examples of these pathogens include Bartonella species, Chlamydia species, Coxiella burnetii, Brucella species, Legionella species, Tropheryma whippleii, and non-Candida fungi.
  • Antibiotic therapy for these pathogens should include aminoglycosides for at least 2 weeks.
  • Therapeutic regimens for Bartonella endocarditis are mentioned below.[2]
Native valve
Ampicillin-Sulbactam 3 g q6h IV x 4–6 weeks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 weeks
OR
Vancomycin 15 mg per kg q12h IV x 4–6 weeks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 week
PLUS
Ciprofloxacin 500 mg q12h PO or 400 mg q12h IV x 4–6 weeks
Native valve pediatric dose
Ampicillin-Sulbactam300 mg per kg per 24 h IV in 4–6 equally divided doses
Gentamicin 1 mg per kg q8h IV/IM
Vancomycin 40 mg per kg per 24 h in 2 or 3 equally divided doses
Ciprofloxacin 10-15 mg per kg q12h IV/PO
Prosthetic valve (early, ≤ 1y)
Vancomycin 15 mg per kg q12h IV x 6
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2weeks
PLUS
Cefepime 2 g q8h IV x 6 weeks
PLUS
Rifampin 300 mg q8h PO/IV x 6 weeks
Prosthetic valve pediatric dose
Vancomycin 40 mg per kg per 24 h IV in 2 or 3 equally divided doses
Gentamicin 1 mg per kg q8h IV/IM
Cefepime 50 mg q8h IV
Rifampin 20 mg per kg per 24 h PO/IV in 3 equally divided doses
Prosthetic valve (late—greater than 1 y) (same regimens as for native valve endocarditis with addition of rifampin)
Ampicillin-Sulbactam 3 g q6h IV x 4–6 weeks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 weeks
PLUS
Rifampin 300 mg q8h PO/IV x 6 weeks
OR
Vancomycin 15 mg per kg q12h IV x 4–6 weeks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 weeks
PLUS
Ciprofloxacin 500 mg q12h PO or 400 mg q12h IV x 4–6 weeks
PLUS
Rifampin 300 mg q8h PO/IV x 6 weeks
Suspected Bartonella, culture negative
Ceftriaxone sodium 2 g per 24 h IV/IM in 1 dose x 6 weeks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 weeks
WITH/WITHOUT
Doxycycline 100 mg per kg q12h IV/PO x 6 weeks
Documented Bartonella, culture positive
Doxycycline 100 mg q12h IV or PO x 6 weeks
PLUS
Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 weeks
Documented Bartonella, culture positive pediatric dose
Ceftriaxone 100 mg per kg per 24 h IV/IM once daily
Gentamicin 1 mg per kg q8h IV/IM
Doxycycline 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses
Rifampin 10 mg per kg q12h PO/IV

References

  1. Braunwald, Eugene; Bonow, Robert O. (2012). Braunwald's heart disease : a textbook of cardiovascular medicin. Philadelphia: Saunders. ISBN 978-1-4377-2708-1.
  2. 2.0 2.1 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter |month= ignored (help)
  3. Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.

Template:WH Template:WS